✦ LIBER ✦

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

✍ Scribed by James R. Berenson; Sundar Jagannath; Bart Barlogie; David T. Siegel; Raymond Alexanian; Paul G. Richardson; David Irwin; Melissa Alsina; S. Vincent Rajkumar; Gordon Srkalovic; Seema Singhal; Steven Limentani; Ruben Niesvizky; Dixie L. Esseltine; Elizabeth Trehu; David P. Schenkein; Kenneth Anderson

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 334 KB
Volume: 104
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21427

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I safety study of enzastaurin pl

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

✍ Irene M. Ghobrial; Nikhil C. Munshi; Brianna N. Harris; Peipei Shi; Nichole M. P 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

Rapid early monoclonal protein reduction

Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression

✍ Jatin Shah; Joan Bladé; Pieter Sonneveld; Jean-Luc Harousseau; Keith Lantz; Anil 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

The efficacy and safety of lenalidomide

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

✍ Meletios Dimopoulos; Adrian Alegre; Edward A. Stadtmauer; Hartmut Goldschmidt; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 1 views

Bortezomib in recurrent and/or refractor

Bortezomib in recurrent and/or refractory multiple myeloma : Initial clinical experience in patients with impaired renal function

✍ Sundar Jagannath; Bart Barlogie; James R. Berenson; Seema Singhal; Raymond Alexa 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB 👁 1 views

Combined pegylated liposomal doxorubicin

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I

The efficacy and safety of bortezomib an

The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens

✍ Giulia Benevolo; Alessandra Larocca; Massimo Gentile; Patrizia Pregno; Francesca 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views